The role of novel biomarker HE4 in endometrial cancer: A case control prospective study

Tumor Biology

Volumn 34, Issue 1, 2013, Pages 571-576

  Angioli, Roberto ^a   Plotti, Francesco ^a   Capriglione, Stella ^a   Montera, Roberto ^a   Damiani, Patrizio ^a   Ricciardi, Roberto ^a   Aloisi, Alessia ^a   Luvero, Daniela ^a   Cafà, Ester Valentina ^a   Dugo, Nella ^a   Angelucci, Michela ^a   Benedetti Panici, Pierluigi ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

CA125; Endometrial cancer; HE4

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; EPIDIDYMAL SECRETORY PROTEIN; HUMAN EPIDIDYMIS SECRETORY PROTEIN 1; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MARKER; ENDOMETRIUM CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 84872776377     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0583-0     Document Type: Article

References (28)

1. F Bray I Dos Santos Silva H Moller E Weiderpass 2005 Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention Cancer Epidemiol Biomarkers Prev. 14 5 1132 1142 15894663 10.1158/1055-9965. EPI-04-0871
2. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun 2009 Cancer statistics, 2009 CA Cancer J Clin. 59 4 225 249 19474385 10.3322/caac.20006
3. CL Creutzberg WL van Putten PC Koper ML Lybeert JJ Jobsen CC Wárlám-Rodenhuis, et al. 2000 Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma Lancet 355 9213 1404 1411 10791524 10.1016/S0140-6736(00)02139-5 1:STN:280:DC%2BD3c3ltVWlsQ%3D%3D
4. A Papanikolaou I Kalogiannidis M Goutzioulis D Misailidou A Makedos I Vergote, et al. 2006 Pelvic lymphadenectomy as alternative to postoperative radiotherapy in high risk early stage endometrial cancer Arch Gynecol Obstet. 274 2 91 96 16518607 10.1007/s00404-006-0138-y 1:STN:280:DC%2BD283hvFGisw%3D%3D
5. R Smith-Bindman E Weiss V Feldstein 2004 How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding Ultrasound Obstet Gynecol. 24 5 558 565 15386607 10.1002/uog.1704 1:STN:280:DC%2BD2crgt1SjtA%3D%3D
6. G Scambia P Benedetti Panici G Baiocchi L Perrone S Greggi S Mancuso 1988 CA 15-3 as a tumor marker in gynecological malignancies Gynecol Oncol. 30 2 265 273 3163666 10.1016/0090-8258(88)90032-7 1:STN:280:DyaL1c3is1WmtA%3D%3D
7. RG Moore AK Brown MC Miller D Badgwell Z Lu WJ Allard, et al. 2008 Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus Gynecol Oncol. 110 2 196 201 18495222 10.1016/j.ygyno.2008.04.002 1:CAS:528:DC%2BD1cXoslWmsbc%3D
8. E Bignotti M Ragnoli L Zanotti S Calza M Falchetti S Lonardi, et al. 2011 Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patiens Br J Cancer. 104 1418 1425 21468050 10.1038/bjc.2011.109 1:CAS:528:DC%2BC3MXlt1GktLo%3D
9. R Drapkin HH von Horsten Y Lin, et al. 2008 Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies PLoS Med. 5 e23 10.1371/journal.pmed.0050023
10. Plotti F, Capriglione S, Terranova C, Montera R, Aloisi A, Damiani P, Muzii L, Scaletta G, Benedetti-Panici P, Angioli R. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumour Biol. 2012 Aug 9.
11. IM Duk 1994 CA125: a useful marker in endometrial carcinoma Am J Obstet Gynaecol Oncol 54 3 321 326
12. A Gadducci M Ferdeghini GF Caenaro C Prontera G Malagnino C Annichiarico, et al. 1992 Immunoacid protein (IAP) as marker for cervical and endometrial carcinoma: alone and in comparison with CA 125 and SCC Cancer J. 5 272 278
13. M Sawada Y Okudaira Y Matsui Y Shimizu 1984 Immunosuppressive acidic protein in patients with gynecologic cancer Cancer 54 4 652 656 6744202 10.1002/1097-0142(1984)54:4<652::AID-CNCR2820540411>3.0.CO;2-C 1:STN:280:DyaL2c3lvVyqsQ%3D%3D
14. N Takeshima Y Shimizu S Umezawa Y Hirai JT Chen I Fujimoto, et al. 1994 Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma Gynecol Oncol. 54 3 321 326 8088608 10.1006/gyno.1994.1217 1:STN:280: DyaK2cznsVOktg%3D%3D
15. G Scambia A Gadducci PB Panici E Foti M Ferdeghini G Ferrandina, et al. 1994 Combined use of CA 125 and CA 15-3 in patients with endometrial carcinoma Gynecol Oncol. 54 3 292 297 8088605 10.1006/gyno.1994.1213 1:STN:280: DyaK2cznsVOksg%3D%3D
16. PL Cherchi S Dessole GA Ruiu G Ambrosini M Farina G Capobianco, et al. 1999 The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma Eur J Gynaecol Oncol. 20 4 315 317 10475131 1:STN:280: DyaK1Mvgt1WitA%3D%3D
17. H Hareyama N Sakuragi S Makinoda S Fujimoto 1996 Serum and tissue measurements of CA72-4 in patients with endometrial carcinoma J Clin Pathol. 49 12 967 970 9038731 10.1136/jcp.49.12.967 1:STN:280:DyaK2s7ptVOksA%3D%3D
18. A Gadducci M Ferdeghini C Prontera P Giordano R Cristofani R Bianchi, et al. 1990 A comparison of pretreatment serum levels of four tumor markers in patients with endometrial and cervical carcinoma Eur J Gynaecol Oncol. 11 4 283 288 2245812 1:STN:280:DyaK3M%2FlvFyltA%3D%3D
19. A Hakala BM Kacinski ER Stanley EI Kohorn U Puistola J Risteli, et al. 1995 Macrophage colony-stimulating factor 1, a clinically useful tumor marker in endometrial adenocarcinoma: comparison with CA 125 and the aminoterminal propeptide of type III procollagen Am J Obstet Gynecol. 173 1 112 119 7631667 10.1016/0002-9378(95)90178-7 1:STN:280:DyaK2MzlvVWrsA%3D%3D
20. C Peters-Engl P Buxbaum E Ogris P Sevelda M Medl 1998 TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer Anticancer Res. 18 6B 4635 4639 9891532 1:CAS:528:DyaK1MXntFyhsw%3D%3D
21. S Ginath J Menczer Y Fintsi E Ben-Shem M Glezerman I Avinoach 2002 Tissue and serum CA125 expression in endometrial cancer Int J Gynecol Cancer. 12 4 372 375 12144685 10.1046/j.1525-1438.2002.01007.x 1:STN:280:DC%2BD38zps1aktw%3D%3D
22. AK Sood RE Buller RA Burger JD Dawson JI Sorosky M Berman 1997 Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome Obstet Gynecol. 90 3 441 447 9277659 10.1016/S0029-7844(97) 00286-X 1:STN:280:DyaK2svitlOitQ%3D%3D
23. CH Hsieh CC ChangChien H Lin EY Huang CC Huang KC Lan, et al. 2002 Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol Oncol. 86 1 28 33 12079296 10.1006/gyno.2002.6664
24. EP Beck M Wagner L Anselmino F Xu RC Bast Jr W Jaeger 1997 Is OVX1 a suitable marker for endometrial cancer? Gynecol Oncol. 65 2 291 296 9159340 10.1006/gyno.1997.4620 1:CAS:528:DyaK2sXjsFOgs7o%3D
25. PM Carpenter GP Gamboa GE Dorion NS Ramsinghani AM Aïssi A Manetta 1996 Radiation-induced CA 125 production by mesothelial cells Gynecol Oncol. 63 3 328 332 8946867 10.1006/gyno.1996.0331 1:CAS:528:DyaK2sXisVWlsA%3D%3D
26. RG Moore CM Miller AK Brown K Robison M Steinhoff G Lambert-Messerlian 2011 Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus Int J Gynecol Cancer. 21 7 1185 1190 21720250
27. E Kalogera N Scholler C Powless A Weaver R Drapkin J Li, et al. 2012 Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer Gynecol Oncol. 124 2 270 275 22037318 10.1016/j.ygyno.2011.10.025 1:CAS:528:DC%2BC38Xht1Whtr8%3D Epub 2011 Oct 28
28. M Kamei S Yamashita K Tokuishi T Hashioto T Moroga S Suehiro, et al. 2010 HE4 expression can be associated with lymph node metastases and disease-free survival in breast cancer Anticancer Res. 30 4779 4783 21115941 1:CAS:528:DC%2BC3MXhs1alug%3D%3D